Philadelphia, Pennsylvania and Oxford, United Kingdom–(Newsfile Corp. – March 12, 2025) – Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the fourth quarter and full year ended December 31, 2024, before the US markets open on Thursday, […]